GT103 and Complement
Prognostic significance of a complement factor H autoantibody in early stage NSCLC. Gottlin EB, Campa MJ, Gandhi R, Bushey RT, Herndon Nd JE, Patz EF Jr.Cancer Biomark. 2022 Jan 14. doi: 10.3233/CBM-210355. Online ahead of print.PMID: 35068447
Tumour extracellular vesicle-derived Complement Factor H promotes tumorigenesis and metastasis by inhibiting complement-dependent cytotoxicity of tumour cells. Mao X, Zhou L, Tey S, Ma A, Yeung C, Ng T, Wong S, Liu B, Fung Y, Patz EF Jr., Cao P, Gao Y, Yam J. J Extracell Vesicles. Oct/Nov 2020 Vol 10, Issue 1. doi.org/10.1002/jev2.12031.
Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody. Winkler MT, Bushey RT, Gottlin EB, Campa MJ, Guadalupe ES, Volkheimer AD, Weinberg JB, Patz EF Jr. PLoS One. 2017 Jun 28; 12(6):e0179841. doi: 10.1371/journal.pone.0179841. eCollection 2017.
A Therapeutic Antibody for Cancer, Derived from Single Human B Cells. Bushey RT, Moody MA, Nicely NL, Haynes BF, Alam SM, Keir ST, Bentley RC, Roy Choudhury K, Gottlin EB, Campa MJ, Liao HX, Patz EF Jr. Cell Rep. 2016 May 17;15(7):1505-1513. doi: 10.1016/j.celrep.2016.04.038. Epub 2016 May 5.
Complement Factor H Antibodies from Lung Cancer Patients Induce Complement-Dependent Lysis of Tumor Cells, Suggesting a Novel Immunotherapeutic Strategy. Campa MJ, Gottlin EB, Bushey RT, Patz EF Jr. Cancer Immunol Res. 2015 Dec;3(12):1325-32. doi: 10.1158/2326-6066.CIR-15-0122. Epub 2015 Jul 27.
Complement factor H autoantibodies are associated with early stage NSCLC. Amornsiripanitch N, Hong S, Campa MJ, Frank MM, Gottlin EB, Patz EF Jr. Clin Cancer Res. 2010 Jun 15;16(12):3226-31. doi: 10.1158/1078-0432.CCR-10-0321. Epub 2010 Jun 1.
Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression. Wang Y, Sun SN, Liu Q, Yu YY, Guo J, Wang K, Xing BC, Zheng QF, Campa MJ, Patz EF Jr., Li SY, He YW. Cancer Discov. 2016 Sep;6(9):1022-35. doi: 10.1158/2159-8290.CD-15-1412. Epub 2016 Jun 13.
Novel genetic variants in HDAC2 and PPARGC1A of the CREB-binding protein pathway predict survival of non-small-cell lung cancer. Tang D, Zhao YC, Qian D, Liu H, Luo S, Patz EF Jr., Moorman PG, Su L, Shen S, Christiani DC, Glass C, Gao W, Wei Q. Mol Carcinog. 2020 Jan;59(1):104-115. doi: 10.1002/mc.23132. Epub 2019 Nov 12. PMID: 31713888
Genetic variants in RUNX3, AMD1 and MSRA in the methionine metabolic pathway and survival in nonsmall cell lung cancer patients. Chen K, Liu H, Liu Z, Luo S, Patz EF Jr., Moorman PG, Su L, Shen S, Christiani DC, Wei Q. Int J Cancer. 2019 Aug 1;145(3):621-631. doi: 10.1002/ijc.32128. Epub 2019 Feb 1. PMID:30650190
Whole Exome Sequencing of Cell-Free DNA for Early Lung Cancer: A Pilot Study to Differentiate Benign From Malignant CT-Detected Pulmonary Lesions. Tailor TD, Rao X, Campa MJ, Wang J, Gregory SG, Patz EF Jr. Front Oncol. 2019 Apr 24;9:317. doi:10.3389/fonc.2019.00317. eCollection 2019. PMID: 31069172
Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival. Qian D, Liu H, Wang X, Ge J, Luo S, Patz EF Jr., Moorman PG, Su L, Shen S, Christiani DC, Wei Q. Int J Cancer. 2019 Apr 15;144(8):1867-1876. doi: 10.1002/ijc.31896. Epub 2018 Dec 8. PMID: 30259978
The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer. Gottlin EB, Bentley RC, Campa MJ, Pisetsky DS, Herndon JE 2nd, Patz EF Jr. J Thorac Oncol. 2011 Oct;6(10):1687-90. doi: 10.1097/JTO.0b013e3182217bec.
A comparative analysis of EGFR-targeting antibodies for gold nanoparticle CT imaging of lung cancer. Ashton JR, Gottlin EB, Patz EF Jr., West JL, Badea CT. PLoS One. 2018 Nov 8;13(11):e0206950. doi: 10.1371/journal.pone.0206950. eCollection 2018. PMID:30408128
Sequential CT Findings in Patients With Non-small-cell Lung Cancer Receiving Nivolumab. Johnson DY, Short RG, Patz EF Jr. Clin Lung Cancer. 2018 Mar;19(2):175-180. doi: 10.1016/j.cllc.2017.10.009. Epub 2017 Oct 28. PMID: 29153896
PEGS Boston (Protein Engineering Summit) Boston, Boston, MA May, 2017
Fleischner Society Annual Meeting, Boston, MA June 2017
IASLC Annual Meeting, Yokohama, Japan October 2017
University of Colorado, Cancer Biology Program, Denver Colorado March, 2018
Stanford University, Canary Center at Stanford, Palo Alto, California May, 2018
Fleischner Society Annual Meeting, Paris France May, 2019
LUNGevity Scientific Retreat. Washington, DC October 2019
Hillman Cancer Center, UPMC, Pittsburgh, PA November, 2019
Cambridge Healthtech Institute Emerging Targets for Immunomodulatory Antibodies, 9th Annual Immuno-Oncology Summit. Boston, MA Oct 2021
Complement-based Drug Development 2021, Oct 2021
P53.05 Inhibition of Tumor Cell Intrinsic Complement Regulatory Proteins Leads to Decreased Tumor Growth in a Mouse Model of NSCLC, 2021 World Conference on Lung Cancer (View Abstract)
Complement as a Natural Adjuvant to Promote Anti-Tumor Immunity in Cancer Therapy, Edward (Ned) F. Patz, Jr., M.D., CEO – Grid Therapeutics, LLC. Presenting at Complement-based Drug Development Summit 2022, September, 2022
Development of Novel Immuno-Oncology Targets from Host B Cells: The Other Side of Autoimmunity, Edward (Ned) Patz, MD, CEO, Grid Therapeutics; Professor, Radiology, Duke University. Presenting at Immuno-Oncology Summit – October, 2022 Boston
Interim Results from a Phase IB, First-in-Human Study of a Novel Complement Factor H Inhibitor (GT103) in Patients with Refractory Non-Small Cell Lung Cancer (NSCLC). Presenting at SITC meeting in Boston, November 2022
Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC), Jeffrey Clarke. 2023 ASCO Annual Meeting